The purpose of this study is to investigate the association between time spent in moderate to vigorous physical activity and markers of cartilage metabolism in the years following anterior cruciate ligament reconstruction.
Participants attend the laboratory on two or three occasions and wear accelerometers for the 10 days in between the first and second laboratory session. The first laboratory session involves urine sample collection, the completion of questionnaires, blood sample collection, acquisition of cross-sectional images of the thigh and calf, and a whole-body composition scan. The researchers will use the accelerometers at the wrist to measure time spent in moderate to vigorous physical activity, and the accelerometers at the ankle as an analogue for knee joint loading. The second laboratory session will consist of a 30-minute run on an instrumented treadmill (measures force of each step taken) whilst wearing non-invasive reflective markers, electromyography devices, and an accelerometer at the ankle. Participants are also invited to undergo optional repeated blood sampling to measure levels of markers of cartilage production and breakdown during rest and in response to a 30-minute run. If participants volunteer for the optional repeated blood sampling, they will be asked to attend a third laboratory session where blood samples will be taken at 24 hours after the run in the second laboratory session.
Study Type
OBSERVATIONAL
Enrollment
80
University of Bath
Bath, United Kingdom
RECRUITINGRatio of urine concentration of c-telopeptide of type II collagen to serum concentration of c-propeptide of type II procollagen
Urine concentration of c-telopeptide of type II collagen (uCTX-II) is a marker of cartilage degradation. Serum concentration of c-propeptide of type II procollagen (sCP-II) is a marker of cartilage synthesis. The ratio between these two biomarkers as an indicator of knee joint health has previously been validated.
Time frame: Day 1
Urine concentration of c-telopeptide of type II collagen
Urine concentration of c-telopeptide of type II collagen (uCTX-II) is a marker of cartilage degradation.
Time frame: Day 1
Serum concentration of c-propeptide of type II procollagen
Serum concentration of c-propeptide of type II procollagen (sCP-II) is a marker of cartilage synthesis.
Time frame: Day 1
Time spent in moderate to vigorous physical activity
Time spent in moderate to vigorous physical activity will be measured using GENEActiv accelerometers worn on the wrist. The devices have previously been validated to quantify physical activity domains.
Time frame: Day 3-10
Step count
Step count will be measured using GENEActiv accelerometers.
Time frame: Day 3-10
Knee joint reaction force
Knee joint reaction force will be measured using musculoskeletal modelling in OpenSim. We will use 3D motion capture to measure joint kinematics, an instrumented treadmill to measure ground reaction forces, and electromyography devices to measure muscle activation.
Time frame: Day 11
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Cumulative knee joint reaction force
We are synchronising data collected by the GENEActiv tri-axial accelerometer with knee joint reaction force during walking and running. We then apply the relationship between these two variables (ascertained during the lab session) to the data collected during the 10 days of wear in free living to provide an estimation of cumulative knee joint reaction force.
Time frame: Days 3-11
Muscle cross-sectional area
We are using peripheral quantitative computerised tomography (pQCT) to measure muscle cross-sectional area. pQCT has previously been validated to measure muscle cross-sectional area.
Time frame: Day 1
Muscle density
We are using peripheral quantitative computerised tomography (pQCT) to measure muscle density. pQCT has previously been validated to measure muscle density.
Time frame: Day 1
Subcutaneous adipose tissue area
We are using peripheral quantitative computerised tomography (pQCT) to measure subcutaneous adipose tissue area. pQCT has previously been validated to measure subcutaneous adipose tissue area.
Time frame: Day 1
Intra-muscular fat content
We are using peripheral quantitative computerised tomography (pQCT) to measure intra-muscular fat content. pQCT has previously been validated to measure intra-muscular fat content.
Time frame: Day 1
Fat mass index
We are using dual-energy x-ray absorptiometry (DEXA) to measure fat mass index. DEXA has previously been validated to measure fat mass index.
Time frame: Day 1
Lean mass index
We are using dual-energy x-ray absorptiometry (DEXA) to measure lean mass index. DEXA has previously been validated to measure lean mass index.
Time frame: Day 1
Knee Injury and Osteoarthritis Outcome Score
The Knee Injury and Osteoarthritis Outcome Score (KOOS) will be used to measure subjective knee joint health. It asks participants to report their symptoms (e.g., pain, stiffness) and function. The KOOS has been validated in a number of populations including those after knee injury.
Time frame: Day 1
Tampa Scale of Kinesiophobia - 11 score
The Tampa Scale of Kinesiophobia - 11 (TSK-11) will be used to measure fear of reinjury/movement. It has been validated in patients with musculoskeletal pain and in knee injury populations.
Time frame: Day 1
English Knee Self-Efficacy Scale score
The English Knee Self-Efficacy Scale (KSES-E) measures knee specific confidence during everyday tasks and physical activity. The KSES-E has been validated in knee injury populations.
Time frame: Day 1
Modified Godin Leisure Time Exercise Questionnaire score
The Modified Godin Leisure Time Exercise Questionnaire (GLTEQ) measures subjective physical activity over a typical seven day period.
Time frame: Day 1
Time spent in lower body resistance training per week
Time spent in lower body resistance training per week will be used to measure subjective time spent in lower body resistance training such as weights or body weight exercise.
Time frame: Day 1
Serum concentration of chondroitin sulphate 846 epitope
Serum concentration of chondroitin sulphate 846 epitope (sCS846) will be measured as marker of aggrecan synthesis.
Time frame: Day 11 and 12
Serum concentration of hyaluronic acid
Serum concentration of hyaluronic acid (HA) will be measured as marker of proteoglycan breakdown.
Time frame: Day 11 and 12